Southern Assam Drug Dealer’s Association organised a trade awareness program

A trade awareness program held at Rajiv Bhawan, Park Road, Silchar, Assam organised by Southern Assam Drug Dealer’s Association. All India Organisation of Chemists & Druggists General Secretary Mr. Suresh Gupta graced the occasion as chief guest. In this awareness program the main issues was Pharmacist & Allied Issues, Drug Policies, GST, Income Tax and Latest Amendments and other issues. Mr. S.S. Gupta told about us

Related Posts

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Max Healthcare Foundation announces fourth edition of Max Medical Scholarship Programme

Max Healthcare Foundation announces fourth edition of Max Medical Scholarship Programme

CDSCO warns against sales of unauthorised toxic cosmetics products from Pakistan

CDSCO warns against sales of unauthorised toxic cosmetics products from Pakistan

Large stock of counterfeit medicines seized from private facility in Bengaluru

Large stock of counterfeit medicines seized from private facility in Bengaluru

Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

Punjab’s Drugs Challenge Shifts, Other States Blamed For Pharma Smuggling

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome